1. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines
- Author
-
Pomykala, Kelsey L, Czernin, Johannes, Grogan, Tristan R, Armstrong, Wesley R, Williams, John, and Calais, Jeremie
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Aging ,Cancer ,Prostate Cancer ,Biomedical Imaging ,Urologic Diseases ,4.2 Evaluation of markers and technologies ,Adult ,Aged ,Aged ,80 and over ,Bone Neoplasms ,Bone and Bones ,Edetic Acid ,Gallium Isotopes ,Gallium Radioisotopes ,Humans ,Image Processing ,Computer-Assisted ,Male ,Middle Aged ,Oligopeptides ,Positron Emission Tomography Computed Tomography ,Practice Guidelines as Topic ,Prostatic Neoplasms ,Retrospective Studies ,Whole-Body Irradiation ,PSMA ,PET/CT ,prostate cancer ,bone metastasis ,field of view ,guidelines ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
Our purpose was to determine the relationship between serum prostate-specific antigen (PSA) level categories (20 ng/mL) and the incidence of bone metastases detected by total-body 68Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT and to assess if expanding the 68Ga-PSMA-11 PET/CT imaging field to include the vertex and lower extremities (total-body acquisition) affects bone metastasis detection rates and patient management. Methods: This was a retrospective analysis of 388 prostate cancer patients enrolled in 5 prospective studies (NCT02940262, NCT03368547, NCT03042312, NCT04050215, and NCT03515577). All underwent 68Ga-PSMA-11 PET/CT scans acquired from vertex to toes for primary staging (n = 93/388, 24%), biochemical recurrence (BCR) localization (n = 225/388, 58%), or restaging metastatic disease (M1) before or during systemic therapy (n = 70/388, 18%) between September 2017 and May 2018. Results: In total, 321 of 388 patients (83%) had a positive 68Ga-PSMA-11 study. PSMA-positive bone lesions were found in 105 of 388 (27%) patients, with an incidence that was positively associated with serum PSA level (
- Published
- 2020